AB0434 RHEUMATOID FACTOR AS PREDICTOR OF RESPONSE TO RITUXIMAB

Background In Rheumatoid Arthritis (RA), the presence of rheumatoid factor (RF) indicate poor prognosis. Strategies searching biomarkers that predict response to biologic therapies allowing selection patients with highest chance for are pertinent. Whether RF is a biomarker RTX disputed. [1] Objectives To investigate whether high (3 times normal) predictive good therapeutic in RA treated Rituximab (RTX). Methods We conducted Retrospective study single rheumatology hospital Morocco. All satisfied ACR-EULAR 2010 classification criteria. Socio-demographic data, comorbidities, disease-related variables (duration, characteristics, and drugs) were collected. The endpoint was decrease DAS28 greater than 1.2 at 6 month after therapy. Statistical analysis performed SPSS 20. Results included 129 mean age 58.45 ± 11.99 years. sex ratio F/M 8:1. duration 17.73 8.34 diagnosis 44.13 13.91 years, 87% seropositive. positivity ACPA 82% 69% respectively. highly elevated 48.4% patients. bivariate analysis, strong significantly associated as assessed by (p=0.002), initial IgM level (p= 0.018). Conclusion our study, positive had better DAS28. These results should be taken into account when making choices. Reference Maneiro RJ, Salgado E, Carmona L, Gomez-Reino JJ. predictor abatacept, rituximab tocilizumab arthritis: Systematic review meta-analysis. Semin Rheum. 2013 Aug;43(1):9-17. doi: 10.1016/j.semarthrit.2012.11.007. Epub Jan 2. PMID: 23290690. Acknowledgements: NIL. Disclosure Interests None Declared.